帕博利珠单抗联合吉西他滨和顺铂化疗方案对肺癌患者T细胞亚群及血清PDCD5、COL4A3水平的影响  

Effects of Pabolizumab Combined with Gemcitabine and Cisplatin on the Expression Levels of T Cell Subsets and Serum PDCD5 and COL4A3 in Patients with Lung Cancer

作　　者：赵孟娟 朱亮杰 陈敬华 ZHAO Mengjuan;ZHU Liangjie;CHEN Jinghua(Oncology Department,the Second People’s Hospital of Luohe,Luohe 462000,China)

机构地区：[1]漯河市第二人民医院肿瘤科,河南漯河462000

出　　处：《河南医学研究》2024年第19期3582-3585,共4页Henan Medical Research

摘　　要：目的研究帕博利珠单抗联合吉西他滨和顺铂(GP)化疗方案对肺癌患者T细胞亚群及血清程序性细胞死亡蛋白5(PDCD5)、Ⅳ型胶原蛋白α3(COL4A3)水平的影响。方法以2020年1月至2022年5月漯河市第二人民医院收治的116例肺癌患者为研究对象,根据治疗方案分为对照组、观察组,各58例。对照组接受GP化疗方案治疗,观察组接受帕博利珠单抗联合GP化疗方案治疗。比较两组临床疗效、治疗前及治疗3个疗程后癌因性疲乏量表(CFS)评分、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、血清细胞因子[糖类抗原125(CA125)、糖类抗原199(CA199)、PDCD5、COL4A3]水平、1 a生存率。结果观察组疾病控制率(DCR)高于对照组(P<0.05);治疗3个疗程后,观察组CFS评分低于对照组(P<0.05),CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)水平低于对照组(P<0.05),血清CA125、CA199、COL4A3水平低于对照组,PDCD5水平高于对照组(P<0.05)。观察组1 a生存率高于对照组(P<0.05)。结论帕博利珠单抗与GP化疗联合治疗肺癌可减轻患者免疫功能损伤,抑制病情进展,缓解癌因性疲乏,增强疗效,延长生存期。Objective To investigate the effects of pabolizumab combined with gemcitabine and cisplatin(GP)on the expression levels of T cell subsets and serum programmed cell death protein 5(PDCD5)and typeⅣcollagenα3(COL4A3)in patients with lung cancer.Methods A total of 116 patients with lung cancer admitted to the Second People’s Hospital of Luohe from January 2020 to May 2022 were divided into control group and observation group according to treatment plan,with 58 cases in each group.The control group was treated with GP chemotherapy,and the observation group was treated with pabolizumab combined with GP chemotherapy.Clinical efficacy,CFS score,T cell subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),serum cytokines[carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),PDCD5,COL4A3]levels,1 year survival rate were compared between the two groups.Results The disease control rate(DCR)of the observation group was higher than that of the control group(P<0.05).After 3 courses of treatment,the CFS score of the observation group was lower than that of the control group(P<0.05),the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher than those of the control group,the level of CD8^(+)was lower than that of the control group(P<0.05),the levels of serum CA125,CA199,and COL4A3 were lower than those of the control group,and the level of PDCD5 was higher than that of the control group(P<0.05).The 1 year survival rate of the observation group was higher than that of the control group(P<0.05).Conclusion Pabolizumab combined with GP chemotherapy in the treatment of lung cancer patients can effectively reduce immune function injury,inhibit disease progression,alleviate cancer-related fatigue,enhance curative effect and prolong survival.

关 键 词：肺癌 帕博利珠单抗 吉西他滨 顺铂 化疗 程序性细胞死亡蛋白5 Ⅳ型胶原蛋白α3 

分 类 号：R734.2[医药卫生—肿瘤]